statistiche ricercatore

COSCIA, MARTA

Distribuzione geografica

Continente	#
NA - Nord America	4.582
AS - Asia	3.632
EU - Europa	1.380
SA - Sud America	503
AF - Africa	95
OC - Oceania	10
Totale	10.202

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	4.434
SG - Singapore	1.797
CN - Cina	612
HK - Hong Kong	611
BR - Brasile	427
VN - Vietnam	318
IT - Italia	272
GB - Regno Unito	263
FR - Francia	232
RU - Federazione Russa	232
FI - Finlandia	110
DE - Germania	96
MX - Messico	84
IN - India	71
CA - Canada	46
BD - Bangladesh	41
NG - Nigeria	38
IQ - Iraq	32
TR - Turchia	30
ZA - Sudafrica	28
SE - Svezia	26
AR - Argentina	24
JP - Giappone	24
NL - Olanda	23
AT - Austria	22
ES - Italia	20
PL - Polonia	20
SA - Arabia Saudita	16
LT - Lituania	14
CO - Colombia	13
IE - Irlanda	13
PK - Pakistan	13
UA - Ucraina	11
UZ - Uzbekistan	11
VE - Venezuela	11
AU - Australia	9
EC - Ecuador	9
CH - Svizzera	7
CL - Cile	7
ID - Indonesia	7
KE - Kenya	7
JO - Giordania	6
AE - Emirati Arabi Uniti	5
EE - Estonia	5
EG - Egitto	5
HN - Honduras	5
MY - Malesia	5
NP - Nepal	5
PH - Filippine	5
MA - Marocco	4
TN - Tunisia	4
BE - Belgio	3
BO - Bolivia	3
CZ - Repubblica Ceca	3
IR - Iran	3
JM - Giamaica	3
MD - Moldavia	3
PE - Perù	3
PS - Palestinian Territory	3
PY - Paraguay	3
BG - Bulgaria	2
CR - Costa Rica	2
DZ - Algeria	2
ET - Etiopia	2
IL - Israele	2
KG - Kirghizistan	2
LB - Libano	2
NI - Nicaragua	2
OM - Oman	2
TT - Trinidad e Tobago	2
UY - Uruguay	2
AM - Armenia	1
BB - Barbados	1
BH - Bahrain	1
CI - Costa d'Avorio	1
DK - Danimarca	1
DO - Repubblica Dominicana	1
GT - Guatemala	1
HU - Ungheria	1
KH - Cambogia	1
KR - Corea	1
KZ - Kazakistan	1
LK - Sri Lanka	1
LY - Libia	1
NZ - Nuova Zelanda	1
PT - Portogallo	1
QA - Qatar	1
SN - Senegal	1
SR - Suriname	1
SV - El Salvador	1
SY - Repubblica araba siriana	1
TG - Togo	1
TL - Timor Orientale	1
TZ - Tanzania	1
Totale	10.202

Salva come PNG Salva come JPEG

Città	#
San Jose	1.493
Singapore	1.006
Hong Kong	601
Chicago	467
Ashburn	390
Dallas	296
The Dalles	249
Boardman	236
Beijing	197
Lauterbourg	196
London	187
Council Bluffs	127
Ho Chi Minh City	117
Helsinki	94
Hanoi	80
Santa Clara	76
Los Angeles	70
Mexico City	63
Orem	53
São Paulo	48
New York	44
Abuja	38
Munich	28
Brooklyn	27
Nuremberg	27
Assago	26
Chennai	26
Manchester	25
Tokyo	23
Frankfurt am Main	22
Denver	21
Johannesburg	21
Milan	21
San Francisco	21
Stockholm	20
Da Nang	19
Warsaw	18
Atlanta	17
Guangzhou	16
Poplar	16
Salt Lake City	16
Boston	15
Haiphong	15
Montreal	15
Shanghai	15
Ankara	14
Houston	14
Turku	14
Baghdad	13
Dublin	13
Shenzhen	13
Amsterdam	11
Belo Horizonte	11
Hangzhou	11
Phoenix	11
Rio de Janeiro	11
Rome	11
Tashkent	11
Tianjin	10
Toronto	10
Elk Grove Village	9
Flanders	9
Porto Alegre	9
Seattle	9
Vergiate	9
Chandler	8
Düsseldorf	8
Moscow	8
Vienna	8
Buffalo	7
Nairobi	7
New Delhi	7
Riyadh	7
Secaucus	7
Zhengzhou	7
Amman	6
Cavaria con Premezzo	6
Charlotte	6
Contagem	6
Fairfield	6
Indianapolis	6
Piracicaba	6
Romola	6
Salvador	6
São José dos Campos	6
Brasília	5
Campinas	5
Campo Grande	5
Caracas	5
Erbil	5
Fort Worth	5
Fortaleza	5
Guidonia Montecelio	5
Jacksonville	5
Jeddah	5
Melbourne	5
Mumbai	5
Ottawa	5
Sterling	5
Varese	5
Totale	7.030

Salva come PNG Salva come JPEG

Nome	#
AISF position paper on HCV in immunocompromised patients	151
Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma	72
Autoimmune hemolytic anemia during bendamustine plus rituximab treatment in CLL patients: multicenter experience	70
Antibody Response to the SARS-CoV-2 Vaccine and COVID-19 Vulnerability during the Omicron Pandemic in Patients with CLL: Two-Year Follow-Up of a Multicenter Study	69
Abstract 2072: Selinexor in combination with chemotherapy or idelalisib elicits a synergistic cytotoxic effect in primary CLL cells	69
Zoledronic acid repolarizes tumor-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway	67
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study	66
Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment	66
HIF-1α is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia	66
AUTOIMMUNE HAEMOLYTIC ANAEMIA DURING BENDAMUSTINE PLUS RITUXIMAB TREATMENT IN CLL PATIENTS	65
A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia	65
B-cell Acute Lymphoblastic Leukemia in Patients with Chronic Lymphocytic Leukemia Treated with Lenalidomide	64
Autoimmune complications in chronic lymphocytic leukemia in the era of targeted drugs	63
SLAMF1/CD150 IS A SIGNALING RECEPTOR EXPRESSED BY A SUBSET OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS CHARACTERIZED BY A FAVORABLE PROGNOSIS	60
AUTOIMMUNE HAEMOLYTIC ANAEMIA DURING BENDAMUSTINE TREATMENT IN CLL PATIENTS	59
B-cell acute lymphoblastic leukemia (B-ALL) in CLL patients treated with lenalidomide	59
Treatment of chronic lymphocytic leukemia in the new drugs era: the state of art in the Italian landscape	59
Adenosine Signaling Mediates Hypoxic Responses in the Chronic Lymphocytic Leukemia Microenvironment	59
Anti-tumor activity of selinexor in combination with antineoplastic agents in chronic lymphocytic leukemia	59
Adoptive immunotherapy with CAR modified T cells in cancer: current landscape and future perspectives	58
Immunotherapeutic strategies in chronic lymphocytic leukemia: advances and challenges	58
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials	57
The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice	57
Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials	57
BTK and PLCG2 remain unmutated in one third of patients with CLL relapsing on ibrutinib	57
Centralized Biobanking Supports Hematology Clinical Trials: the new challenge of the University of Torino	57
A PHASE II MULTI-CENTER TRIAL OF PENTOSTATIN PLUS CYCLOPHOSPHAMIDE WITH OFATUMUMAB (PCO) IN OLDER PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS	57
Zoledronic acid impairs mammary carcinogenesis in BALB/c mice transgenic for the Her-2/neu oncogene	57
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: A GIMEMA, ERIC and UK CLL FORUM study	55
Targeting the mevalonate pathway and downstream signaling pathways as a strategy to circumvent multidrug-resistance in CLL cells	55
Regulation of HIF-1α in TP53 disrupted chronic lymphocytic leukemia cells and its potential role as a therapeutic target	55
Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells	54
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY	54
Immune dysfunctions and immune-based therapeutic interventions in chronic lymphocytic leukemia	54
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study	54
Accelerated activity of the mevalonate pathway supports the immune escape and multidrug-resistance phenotype of IGHV unmutated chronic lymphocytic leukemia cells	53
The bone marrow of myeloma patients is steadily inhabited by a normal-sized pool of functional regulatory T cells irrespective of the disease status	53
IDENTIFICATION AND FUNCTIONAL CHARACTERIZATION OF ANTIBODY IMMUNE RESPONSES ELICITED BY SELF ANTIGENS IN CHRONIC LYMPHOCYTIC LEUKEMIA	53
Effective anti-tumor immunomodulatory properties of zoledronic acid	52
Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy	52
The Mevalonate Pathway and Downstream Signal Transducers As Therapeutic Targets to Overcome Multidrug Resistance in Chronic Lymphocytic Leukemia (CLL)	51
The immunomodulatory molecule TIGIT is expressed by chronic lymphocytic leukemia cells and contributes to anergy	51
Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia	51
Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells	51
Refractory and 17p-deleted chronic lymphocytic leukemia: improving survival with pathway inhibitors and allogeneic stem cell transplantation	50
The PD-1/PD-L1 Axis Contributes to T Cell Dysfunction in Chronic Lymphocytic Leukemia	50
Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study	50
Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: Correlation with biologically-based risk stratification	50
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study	50
Final Report of Bendamustine and Alemtuzumab (BEN CAM) Combination in Relapsed and Refractory Chronic Lymphocytic Leukemia	50
The Mevalonate Metabolic Pathway and the CXCL12/CXCR4 Axis Reciprocally Interact and Are Implicated in Fludarabine Resistance of Chronic Lymphocytic Leukemia Cells	50
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus	49
Continuous venetoclax in treatment‐naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study	49
Chlorambucil PLUS Rituximab As FRONT-LINE Therapy for Elderly and/or Unfit CLL Patients. LONG-TERM Follow-up and Correlation with Biologic-Based Risk Stratification	49
Patients' preferences for chronic lymphocytic leukemia treatment: The CHOICE study	49
The Defective Proliferation of Vgamma9Vdelta2 T Cells to Zoledronic Acid In Chronic Lymphocytic Leukemia (CLL) Is a Powerful Time to First Treatment (TFT) Predictor Associated with the IGHV Mutational Status	49
A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients	49
Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study	48
Pre-existing and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs	48
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL	48
LDH Levels Predict Progression-Free Survival in Treatment-NaIVe Patients with Trisomy 12 Chronic Lymphocytic Leukemia	48
NEW PROSPECTS FOR INDUCTION OF ANTI-LYMPHOMA IMMUNITY USING DNA VACCINES EXPRESSING CHEMOKINE-PARTICLES	48
Prognostic significance of PET/CT in patients with chronic lymphocytic leukemia (CLL) treated with frontline chemoimmunotherapy	48
Identification of Novel Tumor-Associated Antigens in Chronic Lymphocytic Leukemia (CLL) by Serological Proteome Analysis (SERPA)	48
SEROLOGICAL PROTEOME ANALYSIS (SERPA) FOR THE IDENTIFICATION OF TUMOR-ASSOCIATED ANTIGENS ELICITING ANTIBODY-RESPONSES IN CHRONIC LYMPHOCYTIC LEUKEMIA	48
Selinexor in Combination with Chemotherapy or Idelalisib Elicits a Synergistic Cytotoxic Effect in Primary CLL Cells, Also Overcoming Intrinsic and Stromal Cells-Mediated Fludarabine Resistance	48
Myeloma cells drive the maturation of dendritic cells versus a Th2-promoting phenotype which impairs T-cell activation	48
Pre-Existing and Treatment-Emergent Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Drugs	48
Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study	48
The evolving landscape of COVID‐19 and post‐COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL	48
Increased expression of non-functional killer inhibitory receptor CD94 in CD8+ cells of myeloma patients	47
Telomere lenght measurement in the clinically oriented research setting: a comparison between Southern blot (SB), real time quantitative PCR (RQ-PCR) and FLOW-FISH (FF)	47
Impact of immune parameters and immune dysfunctions on the prognosis of patients with chronic lymphocytic leukemia	47
Evaluation of the cytotoxic effect of selinexor in combination with chemotherapy or idelalisib towards primary CLL cells	47
Molecular prediction of durable remission after first-line fludarabinecyclophosphamide-rituximab in chronic lymphocytic leukemia	47
Vγ9Vδ2 T cell-based immunotherapy in hematological malignancies: from bench to bedside	47
Identification and functional characterization of tumor specific antibody responses in chronic lymphocytic leukemia	47
REGULATION OF HIF-1 alpha IN TP53 DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND ITS POTENTIAL ROLE AS A THERAPEUTIC TARGET	47
Slamf-1/CD150 Is a Signaling Receptor Expressed by a Subset of Chronic Lymphocytic Leukemia Patients Characterized by a Favorable Prognosis	47
BTK and PLCG2 mutations in patients with Chronic Lymphocytic Leukemia relapsing on Ibrutinib: a European Research Initiative on CLL (ERIC) study based on real-world evidence	47
Bendamustine and alemtuzumab (BEN CAM) combination in relapsed and refractory chronic lymphocytic leukaemia (CLL): interim report of the italian trial	47
TARGETING HIF-1A AND ITS REGULATORY PATHWAYS AS A STRATEGY TO HAMPER LEUKEMIA-MICROENVIRONMENT INTERACTIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA	47
Progressive telomere shortening occurs during the natural history of chronic lymphocytic leukemia (CLL) and associates to outcome	46
Mutations in NOTCH1 PEST Domain Orchestrate CCL19-Driven Homing of Chronic Lymphocytic Leukemia (CLL) Cells By Modulating the Gene DUSP22	46
Dysfunctional Vγ9Vδ2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells	46
The metabolism of mevalonate as a signaling pathway influencing tumor-host interactions and disease progression in chronic lymphocytic leukemia (CLL)	46
Fludarabine, Cyclophosphamide, Ofatumumab (FC-O2) As Front-Line Treatment for Young and Fit Patients with Chronic Lymphocytic Leukemia (CLL): Preliminary Results of the Prospective Phase 2 LLC0911 Gimema Study	46
TARGETING HIF-1 AND ITS REGULATORY PATHWAYS AS A STRATEGY TO HAMPER TUMOR-MICROENVIRONMENT INTERACTIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA	45
FIRST-LINE TREATMENT CHOICE FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS: WHAT DO CLINICIANS CARE ABOUT? THE CLL FITNESS STUDY	45
High rate of durable responses with undetectable minimal residual disease with frontline venetoclax and rituximab in young and fit patients with chronic lymphocytic leukemia and an adverse biologic profile: results of the gimema phase II LLC1518 - 'Veritas' study	45
ROLE OF THE MEVALONATE PATHWAY IN THE IMMUNOMODULATORY ACTIVITY OF ZOLEDRONIC ACID	45
SELINEXOR (KPT-330) IN COMBINATION WITH CHEMOTHERAPY OR IDELALISIB ELICITS A SYNERGISTIC CYTOTOXIC EFFECT IN PRIMARY CLL CELLS, ALSO OVERCOMING INTRINSIC AND STROMAL CELLS-MEDIATED FLUDARABINE RESISTANCE	45
BENDAMUSTINE AND ALEMTUZUMAB (BEN CAM) COMBINATION IN RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL): PRELIMINARY REPORT OF THE ITALIAN TRIAL	45
IGHV UNMUTATED CLL B CELLS ARE MORE PRONE TO SPONTANEOUS APOPTOSIS AND DEPEND FROM THE ANTI-APOPTOTIC EFFECT OF ENVIRONMENTAL SIGNALS	45
Bendamustine and Alemtuzumab combination in relapsed and refractory chronic lymphocytic leukemia: interim report of the italian trial	44
SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response	44
IMPACT OF THE MEVALONATE PATHWAY AND HIF/PGP AXIS IN MODULATING MULTIDRUG-RESISTANCE IN UNMUTATED CLL CELLS	44
Expression of telomeric proteins in chronic lymphocytic leukemia (CLL)	44
Beyond ibrutinib: novel BTK inhibitors for the treatment of chronic lymphocytic leukemia	44
The Mevalonate Pathway As a Metabolic Target to Circumvent Multidrug-Resistance in Chronic Lymphocytic Leukemia Cells	44
Totale	5.312

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	49.227
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	49.227

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	7	0	0	0	0	0	0	0	0	0	2	1	4
2021/2022	7	0	0	2	0	0	0	0	1	1	1	1	1
2022/2023	23	2	1	3	1	3	3	0	3	5	0	0	2
2023/2024	27	4	5	5	5	6	0	0	1	0	0	0	1
2024/2025	3.434	239	34	868	158	181	118	136	111	283	200	222	884
2025/2026	6.921	411	465	436	846	458	399	2.377	348	788	393	0	0
Totale													10.445